Zastaprazan is under clinical development by Onconic Therapeutics and currently in Phase III for Corrosive Esophagitis (Erosive Esophagitis). According to GlobalData, Phase III drugs for Corrosive Esophagitis (Erosive Esophagitis) have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Zastaprazan’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Zastaprazan is under development for the treatment of gastroesophageal reflux disease (GERD) and gastric ulcers. It is administered through oral route as capsule. The drug candidate is a new molecular entity (NME), it is a potassium-competitive acid blocker (P-CAB).that acts by targeting potassium transporting ATPase alpha.
For a complete picture of Zastaprazan’s drug-specific PTSR and LoA scores, buy the report here.